• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Two-year safety and clinical outcomes in chronic ischemic stroke patients after implantation of modified bone marrow-derived mesenchymal stem cells (SB623): a phase 1/2a study.
CONCLUSIONSIn this completed 2-year phase 1/2a study, implantation of SB623 cells in patients with stable chronic stroke was safe and was accompanied by improvements in clinical outcomes.Clinical trial registration no.: NCT01287936 (clinicaltrials.gov). PMID: 30497166 [PubMed - as supplied by publisher]
Source: Journal of Neurosurgery - November 1, 2018 Category: Neurosurgery Tags: J Neurosurg Source Type: research

Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

How I manage cerebral vasculopathy in children with sickle cell disease
Summary Sickle cell disease induces specific brain alterations that involve both the macrocirculation and the microcirculation. The main overt neurovascular complications in children are infarctive stroke, transient ischaemic attack and cerebral haemorrhage. Silent cerebral infarction, cognitive dysfunction and recurrent headache are also common. Cerebrovascular disease selectively affects children with the HbSS or HbS‐β0 genotypes (i.e. sickle cell anaemia). The incidence of stroke peaks between 2 and 5 years of age (1·02/100 patient‐years) and increases with the severity of the anaemia. Most strokes can be prevent...
Source: British Journal of Haematology - May 5, 2015 Category: Hematology Authors: Valentine Brousse, Manoelle Kossorotoff, Mariane Montalembert Tags: State of the Art Review Source Type: research

Voodoo Medicine: Time To Stop
The world's most celebrated athlete standing on the podium in Rio in honor of receiving yet another gold medal has something important in common with your lazy uncle throwing back a cold one in his Barcalounger. Yes, swimming powerhouse Michael Phelps, purple-spotted from cupping therapy, and your slovenly relative with a beer gut both share a bond -- a weakness in succumbing to the allure of voodoo medicine. Modern-day snake oil salesmen hawking quick cures and TV doctors peddling the latest diet miracle with blatantly ridiculous claims are everywhere on the tube, social media, the supermarket and old-fashioned billboards...
Source: Science - The Huffington Post - August 12, 2016 Category: Science Source Type: news

Brain Peptides for the Treatment of Neuropsychiatric Disorders.
Abstract The realization of the importance of growth factors in adult CNS led to several studies investigating their roles in neuropsychiatric disorders. Based on the observations that chronic stress decreases brain-derived neurotrophic factor (BDNF) and antidepressant treatments reverse BDNF to normal levels, "neurotrophic hypothesis of depression" was proposed. Subsequent studies found that several other growth factors, including fibroblast growth factor (FGF), vascular endothelial growth factor, nerve growth factor were also decreased by chronic stress. Growth factors promote stem cell survival, angiogenesis an...
Source: Current Pharmaceutical Design - November 11, 2018 Category: Drugs & Pharmacology Authors: Karatas H, Yemisci M, Eren-Kocak E, Dalkara T Tags: Curr Pharm Des Source Type: research

Do epilepsy and migraine share a genetic link?
Conclusion This paper suggests there is a link between the number of close relatives with a seizure disorder and the likelihood that an individual with epilepsy will also suffer from migraines with aura. However, it seems that the researchers were only interested in what they term ‘additional’ family members, and did not take into account the fact that to be eligible for this study at least two siblings or a parent and child both had to suffer from epilepsy. There seems to be the possibility that if, for example, four members of a family were enrolled in the study but the family had no further affected members, all me...
Source: NHS News Feed - January 7, 2013 Category: Consumer Health News Tags: Neurology Genetics/stem cells Source Type: news

Targeting pericytes for therapeutic approaches to neurological disorders
AbstractMany  central nervous system diseases currently lack effective treatment and are often associated with defects in microvascular function, including a failure to match the energy supplied by the blood to the energy used on neuronal computation, or a breakdown of the blood–brain barrier. Pericytes, an u nder-studied cell type located on capillaries, are of crucial importance in regulating diverse microvascular functions, such as angiogenesis, the blood–brain barrier, capillary blood flow and the movement of immune cells into the brain. They also form part of the “glial” scar isolating damaged parts of the CN...
Source: Acta Neuropathologica - August 10, 2018 Category: Neurology Source Type: research

Introduction to Purinergic Signaling.
Abstract Purinergic signaling was proposed in 1972, after it was demonstrated that adenosine 5'-triphosphate (ATP) was a transmitter in nonadrenergic, noncholinergic inhibitory nerves supplying the guinea-pig taenia coli. Later, ATP was identified as an excitatory cotransmitter in sympathetic and parasympathetic nerves, and it is now apparent that ATP acts as a cotransmitter in most, if not all, nerves in both the peripheral nervous system and central nervous system (CNS). ATP acts as a short-term signaling molecule in neurotransmission, neuromodulation, and neurosecretion. It also has potent, long-term (trophic) ...
Source: Mol Biol Cell - October 27, 2019 Category: Molecular Biology Authors: Burnstock G Tags: Methods Mol Biol Source Type: research

Pannexin ‐1 in the CNS: emerging concepts in health and disease
AbstractPannexin ‐1 (Panx1) is a large pore membrane channel with unique conduction properties ranging from non‐selective ion permeability to the extracellular release of signalling molecules. The release of ATP by Panx1 has been particularly well‐characterized with implications in purine signalling across a v ariety of biological contexts. Panx1 activity is also important in inflammasome formation and the secretion of pro‐inflammatory molecules such as interleukin‐1β. Within the central nervous system (CNS), Panx1 is expressed on both neurons and glia, and is thought to mediate crosstalk between the se cells. A...
Source: Journal of Neurochemistry - March 14, 2020 Category: Neuroscience Authors: Albert K. Yeung, Chetan S. Patil, Michael F. Jackson Tags: REVIEW ARTICLE Source Type: research

U.S. FDA Approves TECVAYLI ™ (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
HORSHAM, Pa., October 25, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) approved TECVAYLI™ (teclistamab-cqyv) for the treatment of adult patients with relapsed or refractory multiple myeloma, who previously received four or more prior lines of therapy, including a proteasome inhibitor, immunomodulatory drug and anti-CD38 monoclonal antibody.1 TECVAYLI™ is a first-in-class, bispecific T-cell engager antibody that is administered as a subcutaneous treatment.1 This off-the-shelf (or ready to use) therapy uses innovative science to ac...
Source: Johnson and Johnson - October 25, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news